Torrent Pharmaceuticals Limited has informed the Exchange about Investor Presentation
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals has shared its analyst presentation for Q1 FY2025-26 (quarter ended 30th June 2025) with the exchanges. Total consolidated revenue grew 11% year-on-year to Rs 3,178 crore, up from Rs 2,859 crore in Q1 FY25. The India business led with Rs 1,811 crore (up 11%), while the United States grew the fastest at 19% to Rs 308 crore. Germany, Brazil, and Other markets also posted steady growth of 9-11% each. The filing is a routine disclosure of the investor deck following the quarterly results announcement.
The double-digit revenue growth across all key markets signals healthy business momentum, which is mildly positive for shareholders. However, since this is just the presentation filing without margin or profit details, the immediate stock impact is likely limited.